Advertisement

Topics

Spectrum Pharma Announces Completion Of Enrollment In The Phase III Pivotal Study (ADVANCE) Of ROLONTIS (Eflapegrastim), A Novel Long-Acting GCSF

20:00 EDT 31 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Spectrum Pharma Announces Completion Of Enrollment In The Phase III Pivotal Study (ADVANCE) Of ROLONTIS (Eflapegrastim), A Novel Long-Acting GCSF

NEXT ARTICLE

More From BioPortfolio on "Spectrum Pharma Announces Completion Of Enrollment In The Phase III Pivotal Study (ADVANCE) Of ROLONTIS (Eflapegrastim), A Novel Long-Acting GCSF"

Quick Search
Advertisement